Sharp Therapeutics Corp. (TSXV:SHRX)
Canada
· Delayed Price · Currency is CAD 1.700
+0.050 (3.03%)
At close: Apr 24, 2025
Sharp Therapeutics Company Description
Sharp Therapeutics Corp., a biology technology company, develops medicines specific for genetic diseases.
It engages in the development of the CoreX biology, AlloChem chemistry, and Disco/Mine computational technologies to discover drugs that activate the protein altered by gene mutation.
Sharp Therapeutics Corp. is based in Pittsburgh, Pennsylvania.
Sharp Therapeutics Corp.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Scott Sneddon |
Contact Details
Address: 2403 Sidney Street Pittsburgh, Ontario 15203 United States | |
| Phone | 412-206-5303 |
| Website | sharptx.com |
Stock Details
| Ticker Symbol | SHRX |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Dr. Scott F. Sneddon J.D., Ph.D. | Chief Executive Officer, Chief Science Officer and Director |
| Marcel P. Bruchez Ph.D. | Scientific Co-Founder and Chief Technology Officer |
| Dr. Alan S. Waggoner Ph.D. | Scientific Co-Founder and Chief Architect |
| Edward Jonasson CA CPA | Chief Financial Officer |
| Lorne Michael Sugarman | Director and Corporate Secretary |